A First-In-Human Study of LY3839840 in Healthy Participants
← catalyst calendarSponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Double · Basic science
Enrollment
140actual
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-04 | actual | When the study began enrolling |
| Primary completion | 2025-05-22 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-22 | actual | The whole study's end, after follow-up |
| First posted | 2023-12-01 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy
Interventions
- Drug: LY3839840
- Drug: Placebo
- Drug: Midazolam
Primary outcome
what the primary-completion date above is the date OFNumber of participants with one or more Adverse Event (s) (AEs), Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration
measured Baseline up to Week 8
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed